MAP2K7 and melanoma: For example, the IMspire150 trial56 showed an increased risk of quality-of-life deterioration for patients with melanoma who received ICIs in combination with anti-BRAF and anti-MEK targeted therapy because of the high risk of adverse events reported for this specific combination of drugs.